{{Rsnum
|rsid=1362931
|Gene=PLA2G7
|Chromosome=6
|position=46714342
|Orientation=plus
|GMAF=0.1713
|Gene_s=PLA2G7
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.9 | 38.9 | 60.2
| HCB | 1.5 | 24.8 | 73.7
| JPT | 0.9 | 18.8 | 80.4
| YRI | 1.4 | 25.2 | 73.5
| ASW | 0.0 | 28.1 | 71.9
| CHB | 1.5 | 24.8 | 73.7
| CHD | 3.7 | 19.3 | 77.1
| GIH | 5.9 | 15.8 | 78.2
| LWK | 2.7 | 22.7 | 74.5
| MEX | 1.7 | 29.3 | 69.0
| MKK | 2.6 | 17.9 | 79.5
| TSI | 7.8 | 40.2 | 52.0
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23118302
  |Trait=Lipoprotein-associated phospholipase A2 activity and mass
  |Title=Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
  |RiskAllele=A
  |Pval=3E-19
  |OR=.02
  |ORtxt=[0.016-0.030] ng/ml increase
  }}

{{PMID Auto
|PMID=18204052
|Title=Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}